U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C6H14N4O2.C5H6O5
Molecular Weight 494.5001
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIARGININE OXOGLURATE

SMILES

OC(=O)CCC(=O)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O

InChI

InChIKey=NCRWNFFIHNRODM-SCGRZTRASA-N
InChI=1S/2C6H14N4O2.C5H6O5/c2*7-4(5(11)12)2-1-3-10-6(8)9;6-3(5(9)10)1-2-4(7)8/h2*4H,1-3,7H2,(H,11,12)(H4,8,9,10);1-2H2,(H,7,8)(H,9,10)/t2*4-;/m00./s1

HIDE SMILES / InChI

Molecular Formula C5H6O5
Molecular Weight 146.0981
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H14N4O2
Molecular Weight 174.201
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.

CNS Activity

Curator's Comment: L-Arginine has the ability to cross the blood brain barrier.

Originator

Curator's Comment: Arginine was first isolated from a lupin seedling extract in 1886 by the German chemist Ernst Schultze.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q5T6X5
Gene ID: 222545.0
Gene Symbol: GPRC6A
Target Organism: Homo sapiens (Human)
44.1 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
310 μM
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
6219 μM
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
882 μM
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
24788 M × min
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
265435 M × min
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
38223 M × min
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77.5 min
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
41.6 min
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
59.6 min
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
ARGININE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis...
AEs leading to
discontinuation/dose reduction:
Cardiopulmonary arrest
Metabolic acidosis (acute)
Hyponatremia (severe)
Sources: Page: p.621
200 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg/kg, 3 times / day
Sources: Page: p.63
unhealthy, 24
n = 11
Health Status: unhealthy
Condition: Cystic fibrosis
Age Group: 24
Sex: M+F
Population Size: 11
Sources: Page: p.63
15 g 2 times / day multiple, oral
Studied dose
Dose: 15 g, 2 times / day
Route: oral
Route: multiple
Dose: 15 g, 2 times / day
Sources: Page: p.1
healthy, 34 ± 2.6
n = 12
Health Status: healthy
Condition: Dietary supplementation
Age Group: 34 ± 2.6
Sex: M+F
Population Size: 12
Sources: Page: p.1
7 g 3 times / day multiple, oral
Studied dose
Dose: 7 g, 3 times / day
Route: oral
Route: multiple
Dose: 7 g, 3 times / day
Sources: Page: p.200
unhealthy, 43± 16
n = 10
Health Status: unhealthy
Condition: Hypercholesterolaemia
Age Group: 43± 16
Sex: M+F
Population Size: 10
Sources: Page: p.200
DLT: Gastrointestinal discomfort...
Dose limiting toxicities:
Gastrointestinal discomfort (20%)
Sources: Page: p.200
AEs

AEs

AESignificanceDosePopulation
Cardiopulmonary arrest Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Metabolic acidosis acute
Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Hyponatremia severe
Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Gastrointestinal discomfort 20%
DLT
7 g 3 times / day multiple, oral
Studied dose
Dose: 7 g, 3 times / day
Route: oral
Route: multiple
Dose: 7 g, 3 times / day
Sources: Page: p.200
unhealthy, 43± 16
n = 10
Health Status: unhealthy
Condition: Hypercholesterolaemia
Age Group: 43± 16
Sex: M+F
Population Size: 10
Sources: Page: p.200
PubMed

PubMed

TitleDatePubMed
A rare case of complete human erythrocyte AMP deaminase deficiency due to two novel missense mutations in AMPD3.
2001
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.
2001 Feb 2
DNA recognition by the methyl-CpG binding domain of MeCP2.
2001 Feb 2
Alteration of humoral and peripheral vascular responses during graded exercise in heart failure.
2001 Jan
Relationship between flow rate and NO production in postnatal mesenteric arteries.
2001 Jan
Altered TNF-alpha, glucose, insulin, and amino acids in islets of Langerhans cultured in a microgravity model system.
2001 Jan
Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.
2001 Jan 1
Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain.
2001 Jan 1
Strain is more important than electrostatic interaction in controlling the pKa of the catalytic group in aspartate aminotransferase.
2001 Jan 16
Strengthened arm-dimerization domain interactions in AraC.
2001 Jan 26
The role of nitric oxide in bradycardia of rats with obstructive cholestasis.
2001 Jan 5
The function of Arg-94 in the oxidation and decarboxylation of glutaryl-CoA by human glutaryl-CoA dehydrogenase.
2001 Jan 5
C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production.
2001 Jan 9
Acetaldehyde, a metabolite of ethanol, activates the hypothalamic-pituitary-adrenal axis in the rat.
2001 Jan-Feb
Identification of the collagen-binding site of the von Willebrand factor A3-domain.
2001 Mar 30
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa.
2001 Mar 9
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride. https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration: Oral
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:57:37 GMT 2023
Edited
by admin
on Sat Dec 16 09:57:37 GMT 2023
Record UNII
I9LFI257OB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIARGININE OXOGLURATE
Common Name English
DIARGININE .ALPHA.-KETOGLUTARATE
Common Name English
L-ARGININE ALPHA KETO-GLUTARATE 2:1
Common Name English
ARGININE HEMOXOGLURATE
Common Name English
GLUTARIC ACID, 2-OXO-, COMPD. WITH ARGININE (1:2)
Systematic Name English
DIARGININE .ALPHA.-OXOGLUTARATE
Common Name English
ARGININE AKG 2:1
Common Name English
PENTANEDIOIC ACID, 2-OXO-, COMPD. WITH L-ARGININE (1:2)
Systematic Name English
DI-ARGICETO
Brand Name English
L-ARGININE, 2-OXOPENTANEDIOATE (2:1)
Systematic Name English
ARGININE AKG
Common Name English
L-ARGININE ALPHA-KETOGLUTARATE (2:1)
Common Name English
EUCOL
Brand Name English
DIARGININE OXOGLUTARATE
Common Name English
Classification Tree Code System Code
DSLD 2391 (Number of products:239)
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
DSLD 2618 (Number of products:151)
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
Code System Code Type Description
PUBCHEM
9957390
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
PRIMARY
CAS
556834-44-7
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
NON-SPECIFIC STOICHIOMETRY
CAS
533909-24-9
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
NON-SPECIFIC STOICHIOMETRY
CAS
5256-76-8
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
PRIMARY
ECHA (EC/EINECS)
226-059-4
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
PRIMARY
FDA UNII
I9LFI257OB
Created by admin on Sat Dec 16 09:57:37 GMT 2023 , Edited by admin on Sat Dec 16 09:57:37 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY